Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.

Journal Article

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 microg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

Full Text

Duke Authors

Cited Authors

  • Smith, MA; Morton, CL; Kolb, EA; Gorlick, R; Keir, ST; Carol, H; Lock, R; Kang, MH; Reynolds, CP; Maris, JM; Watkins, AE; Houghton, PJ

Published Date

  • February 2010

Published In

Volume / Issue

  • 54 / 2

Start / End Page

  • 307 - 310

PubMed ID

  • 19856388

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.22188

Language

  • eng

Conference Location

  • United States